Talkspace (TALK) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
9 Mar, 2026Executive summary
Universal Health Services (UHS) has entered into a definitive agreement to acquire Talkspace for $5.25 per share, valuing the transaction at approximately $835 million, to be financed through UHS's existing credit facility.
The acquisition aims to create a nationally scaled, end-to-end continuum in behavioral healthcare, expanding access and integrating virtual and outpatient services.
Talkspace, with 6,000 licensed professionals, generated $229 million in revenue and delivered over 1.6 million therapy and psychiatry sessions in 2025.
The transaction is expected to be slightly accretive to UHS's adjusted net income per diluted share in the first year post-closing and increasingly accretive thereafter.
Closing is anticipated in the third quarter of 2026, pending shareholder and regulatory approvals.
Voting matters and shareholder proposals
The merger requires approval by Talkspace's stockholders, with proxy materials to be filed and distributed for voting.
Investors are urged to review the proxy statement and related SEC filings for important information regarding the transaction.
Board of directors and corporate governance
The transaction was unanimously approved by the Boards of Directors of both UHS and Talkspace.
Directors, executive officers, and certain employees may be deemed participants in the proxy solicitation for the merger.
Latest events from Talkspace
- Board unanimously recommends approval of $5.25/share cash merger with UHS; key holders support.TALK
Proxy filing20 Apr 2026 - Stockholders to vote on $5.25/share cash merger with UHS, with board unanimous support and fairness opinion.TALK
Proxy filing7 Apr 2026 - Definitive agreement for acquisition by UHS to create a national behavioral health continuum.TALK
Proxy Filing9 Mar 2026 - Shareholders to receive $5.25 per share in all-cash merger, pending approvals and clearances.TALK
Proxy Filing9 Mar 2026 - 2025 revenue up 22% to $229M, adjusted EBITDA up 127%, with strong 2026 growth outlook.TALK
Q4 202519 Feb 2026 - Director elections, auditor ratification, and executive pay were key agenda items.TALK
AGM 20243 Feb 2026 - Q2 revenue up 29%, net loss narrowed, and share repurchase authority expanded to $32M.TALK
Q2 20242 Feb 2026 - Q3 revenue up 23% to $47.4M, net income positive, Payor segment drives growth.TALK
Q3 202418 Jan 2026 - AI-driven solutions and payer partnerships drive growth and position the platform for leadership.TALK
44th Annual J.P. Morgan Healthcare Conference15 Jan 2026